HOME >> BIOLOGY >> NEWS
Other highlights in the February 18 issue of JNCI

Two Studies Examine Aspirin for Cancer Prevention

Two studies in the February 18 issue of JNCI address the association between aspirin use and the risk of two different types of cancer.

In one study, Ellen T. Chang, Sc.D., of the Harvard School of Public Health, and colleagues examined the association between various pain relievers and the risk of Hodgkin's lymphoma. In a case-control study, participants were asked to report their average use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) and of acetaminophen over the previous 5 years. They found that the risk of Hodgkin's lymphoma was lower with regular aspirin use (2 or more tablets per week) than with non-regular aspirin use, and that there was no association between risk of Hodgkin's lymphoma and use of other non-aspirin NSAIDs, but the risk was higher with regular acetaminophen use.

"If aspirin use is indeed found to protect against Hodgkin's lymphoma, this relationship could afford insight into the pathogenesis of the disease and offer possible clues toward its prevention," the authors write.

In a second study, Chin Hur, M.D., of Massachusetts General Hospital, and colleagues examined the cost-effectiveness of aspirin as a chemoprevention strategy for esophageal cancer in patients with Barrett's esophagus. Patients with Barrett's esophagus are at an increased risk for esophageal cancer and, as such, often undergo periodic endoscopic screening. Aspirin use has been associated with a reduced risk of esophageal cancer, but the use of aspirin can cause bleeding and other harms.

Using a model analysis to compare the effectiveness and cost-effectiveness of aspirin for the chemoprevention of esophageal cancer in patients with Barrett's esophagus, Hur and colleagues found that aspirin therapy with or without endoscopic surveillance was both more effective (in terms of quality-adjusted life years) and cost less than no therapy or just endoscopic
'"/>

Contact: Katherine Arnold
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
17-Feb-2004


Page: 1 2 3

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the July 7 JNCI
5. Other highlights in the June 16 JNCI
6. Other Highlights in the June 2 JNCI
7. Other highlights in the May 19 JNCI
8. Other highlights in the May 5 JNCI
9. Other highlights of the March 17 issue of JNCI
10. Other highlights in the March 3 issue of JNCI
11. Other highlights in the February 4 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market Intelligence ... Biometrics and Digital Identity".  Acuity characterizes 2017 as ... when increased adoption reflects a new understanding of ... "Biometrics and digital identity are often perceived ... Maxine Most , Principal of Acuity Market intelligence. ...
(Date:1/24/2017)...  It sounds simple and harmless—an electronic sensor ... signs and alerts parents on their smart phones ... drops. But pediatric experts argue that such devices ... evidence of medical benefits, especially to healthy babies. ... parents of healthy babies, promising peace of mind ...
(Date:1/19/2017)... and PUNE, India , January 19, 2017 /PRNewswire/ ... titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," the ... at a CAGR of 9.6% from 2016 to 2022. In 2015, ... to high-level security for both public and private sectors. ... ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... ... ... The Catalyst Midwest premix manufacturing facility has been certified as organic, ... label organic services. , The first organic product is Organic 18 Percent Layer Feed, ... Marketing, which owns the facility. , Catalyst already has received the Safe Feed/Safe ...
(Date:2/24/2017)... ... February 24, 2017 , ... A study recently ... in an ambulatory surgery center (ASC) with satisfactory clinical and patient-reported outcomes, when ... studies. , Jake Lubinski, president of AxioMed, commented on the recent publication, ...
(Date:2/24/2017)... Feb. 24, 2017 Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... to participate in its previously announced rights offering ... shares of common stock and Series C Convertible ... listed warrants. As previously announced, ...
(Date:2/24/2017)... Feb. 24, 2017  Driven by consumers, preference ... now the fastest growing categories, finds the recently ... in Personal Care: Multi-regional Market Analysis and Opportunities ... consulting firm Kline. "Biotechnology actives are ... them more effective for skin and hair care ...
Breaking Biology Technology:
Cached News: